Beta Bionics, Inc.

What they do

Beta Bionics designs, develops and commercializes the iLet Bionic Pancreas, cleared by the FDA in May 2023 for Type 1 diabetes in adults and children six and older and launched commercially in the U.S. in May 2023. The iLet uses adaptive closed-loop algorithms to autonomously determine every insulin dose every five minutes without requiring users to count carbohydrates; only body weight is needed for initialization. Revenue comes from the iLet device plus separately sold single-use products (insulin cartridges and infusion sets, generally replaced every 2-3 days) and a companion mobile application. Use of the iLet requires a separately purchased compatible third-party iCGM, with integrations for Dexcom G6/G7 and Abbott FreeStyle Libre 3 Plus.

Revenue drivers

• Durable Medical Equipment (DME) channel — Largest channel: $20.4M of net sales in Q2 2026, up 9% year over year from $18.6M. Represents reimbursement through traditional durable medical equipment benefits.
• Pharmacy Benefit Plan (PBP) channel — $11.6M in Q2 2026, up 153% from $4.6M in Q2 2025, making it the faster-growing channel and roughly a third of quarterly sales.
• Single-use consumables — Cartridges and infusion sets sold separately to iLet customers, generally disposed of every 2-3 days, generating recurring revenue tied to the installed base of 35,011 iLets as of December 31, 2025.
• iLet device sales to new patients — New patient starts drive device revenue; Q2 2026 starts rose at least 10% but less than 20% sequentially, with 69% coming from people previously on multiple daily injections and a high-30s percentage reimbursed through the PBP channel.

Recent performance

Second quarter 2026 net sales were $32.0 million, up 38% from $23.2 million in Q2 2025, with DME channel sales of $20.4 million (+9%) and PBP channel sales of $11.6 million (+153%). Gross margin was 59.0%, up 524 basis points from 53.8% a year earlier. Loss from operations was $25.6 million (negative 80% of sales) versus $19.9 million a year ago, and net loss was $23.4 million (negative 73% of sales), matching the prior-year net loss margin of negative 73%. Adjusted EBITDA was negative $17.7 million (negative 55% of sales) versus negative $14.5 million (negative 63% of sales) in Q2 2025. Cash, cash equivalents, short and long-term investments totaled $225.2 million as of June 30, 2026, against reported cash and equivalents of $44.3 million and total assets of $292.4 million on the same balance sheet date.

Strategy

The company is expanding the iLet beyond Type 1 diabetes: in July 2026 it initiated enrollment in a pivotal trial of the iLet in adults with Type 2 diabetes in the U.S., with an expected indication expansion around mid-year 2027 subject to FDA clearance. It announced updated expectations to fully commercialize Mint, its patch pump in development, by the end of the second quarter of 2027, subject to FDA clearance, and says Mint manufacturing capacity is expected to meet anticipated demand at full launch. It published a near real-time real-world data dashboard on its website, which it describes as a new standard for data transparency in the Automated Insulin Delivery category. A Phase 2a feasibility trial of its bihormonal system in New Zealand, initiated in Q1 2026, identified opportunities to improve the glucagon asset's excipient profile and the bihormonal dosing algorithm, with improvements expected to take less than one year before additional feasibility trials. The company maintains a stated goal of growing PBP reimbursement, guiding 37% to 39% of new patient starts through that channel for 2026.

Risks

• Narrow current indication — The iLet is FDA-cleared only for Type 1 diabetes in patients six and older, so the U.S. Type 2 opportunity depends on a pivotal trial and clearance expected around mid-year 2027.
• Persistent operating losses — Net loss was $73.2 million in 2025 and $23.4 million in Q2 2026 alone, with operating cash flow negative $50.9 million in 2025, so the company funds operations from its balance sheet.
• New product execution and timing — Mint patch pump commercialization is targeted for the end of Q2 2027 and bihormonal improvements are expected to take under a year before new feasibility trials, both subject to regulatory clearance and timing risk.
• Dependence on third-party sensors — Use of the iLet requires an independently purchased compatible iCGM, with integrations limited to Dexcom G6/G7 and Abbott FreeStyle Libre 3 Plus, so sensor availability or terms affect the product experience.

Outlook

Management reiterated full year 2026 revenue guidance of approximately $131 million to $136 million and PBP guidance of 37% to 39% of new patient starts, both unchanged from prior guidance. Gross margin guidance was raised to 58.5% to 59.5% from a previous 57.5% to 59.5%. The company expects the iLet Type 2 indication to expand around mid-year 2027 and full commercialization of the Mint patch pump by the end of Q2 2027, both subject to FDA clearance.